Insight A Conversation with WIT’s ITC Practice Chair: Examining 2024 Trends in Section 337 Investigations
Insights Home Insights Featured Content Event ACI’s 21st Annual Paragraph IV Disputes Conference WIT Legal will sponsor lanyards and the day one luncheon at ACI's 21st Annual Paragraph IV Disputes Conference on April 29 and 30, 2025. Q&As A Conversation with WIT’s Hatch-Waxman Practice Chair: Examining 2024 ANDA Litigation Activity Recently, we spoke to our Hatch-Waxman Practice Chair, Michael Crowe, to gain insights into Hatch-Waxman litigation trends in 2024. Here’s what he had to say about filings and possible trends in the year ahead. Case Study- Technology Case Study: Payment Systems Expert Needed for Trade Secret Dispute Between Technology Companies In a federal trade secret dispute, a payment technology company alleged that former senior executives stole trade secrets and proprietary information to establish a competing payment platform. Report WIT Hatch-Waxman Report: Judge Michael Shipp Our latest Hatch-Waxman report provides a comprehensive analysis of Judge Michael Shipp's activity at the United States District Court for the District of New Jersey since his appointment in July 2012. Learn more about our findings. Blog Expert Qualifications Under Revised FRE 702: A Look at Recent Cases The 2023 amendment to Federal Rule of Evidence (FRE) 702 has introduced stricter standards for expert testimony, challenging litigators to adapt to the evolving requirements. Let’s take a look at five recent cases to see how courts are putting these requirements into practice—insights that will prove particularly valuable for litigators planning their expert strategy. Insights & News All Industries Automotive Financial Technology Gaming Healthcare Technology Pharmaceutical Wireless Communications Medical Devices All Trends 5G / 6G Banking Crisis COVID-19 Cryptocurrency Drug and Vaccine Development Election Law and Voting Rights Electric Vehicles FDA-Regulated Drugs and Devices Mobile Gaming Payment Systems Virtual Reality Wearable Devices All Insight Types Archive Blog Case Study Case Study- Life Sciences Case Study- Technology Event In the News Other Content Press Release Q&As Report Video Search December 18, 2024 — Report WIT Hatch-Waxman Report: Judge Michael Shipp Our latest Hatch-Waxman report provides a comprehensive analysis of Judge Michael Shipp's activity at the United States District Court for the District of New Jersey since his appointment in July 2012. Learn more about our findings. October 23, 2024 — Blog Life Sciences Roundup: Top Insights from Q2 – Q3 Life sciences companies face mounting litigation over patents, products, and pricing practices. Successfully navigating these matters requires expertise from qualified experts and an expert agency focused on arising litigation trends. Check out our insights. June 18, 2024 — Report A National Study of Community Attitudes Toward Pharmaceutical Companies WIT commissioned the DOAR Research Center to conduct a national study of community attitudes toward pharmaceutical companies and several issues suspected of creating bias. Learn more about their findings. June 12, 2024 — Report WIT Hatch-Waxman Report: Senior Judge Richard Andrews Our latest Hatch-Waxman report provides a comprehensive analysis of Senior Judge Richard Andrews' activity at the United States District Court for the District of Delaware since his appointment in November 2011. Learn more about our findings. October 2, 2023 — Blog Expert Perspective: What is Driving Growth and Litigation in the Biotechnology Space? The biotechnology market is headed towards transformational growth as the landscape shifts, resulting from impending patent cliffs, increased M&A activity, and ongoing innovation. WIT biotech expert Peter Lankau provides insights on what's to come in the industry for the remainder of this year and beyond. July 26, 2023 — Blog Big Pharma’s Balancing Act: Navigating Patent Thickets in the Age of Biosimilars Biosimilar patent cases are complex legal battles that require the support of various experts to bolster the nuanced arguments presented by pharmaceutical companies. May 17, 2023 — Blog Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more. April 4, 2023 — Press Release WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets. February 22, 2023 — Blog Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP. July 14, 2021 — Blog FDA Approvals, Controversial Therapeutics, and the Experts Needed for Litigation Therapeutics are some of the most complicated, most regulated, and most litigated products existing in the market today. Any inconsistencies to the qualification and validation protocols of the product can cause undue harm, lasting damage, and unlimited claims of liability. Load More Loading...
Event ACI’s 21st Annual Paragraph IV Disputes Conference WIT Legal will sponsor lanyards and the day one luncheon at ACI's 21st Annual Paragraph IV Disputes Conference on April 29 and 30, 2025.
Q&As A Conversation with WIT’s Hatch-Waxman Practice Chair: Examining 2024 ANDA Litigation Activity Recently, we spoke to our Hatch-Waxman Practice Chair, Michael Crowe, to gain insights into Hatch-Waxman litigation trends in 2024. Here’s what he had to say about filings and possible trends in the year ahead.
Case Study- Technology Case Study: Payment Systems Expert Needed for Trade Secret Dispute Between Technology Companies In a federal trade secret dispute, a payment technology company alleged that former senior executives stole trade secrets and proprietary information to establish a competing payment platform.
Report WIT Hatch-Waxman Report: Judge Michael Shipp Our latest Hatch-Waxman report provides a comprehensive analysis of Judge Michael Shipp's activity at the United States District Court for the District of New Jersey since his appointment in July 2012. Learn more about our findings.
Blog Expert Qualifications Under Revised FRE 702: A Look at Recent Cases The 2023 amendment to Federal Rule of Evidence (FRE) 702 has introduced stricter standards for expert testimony, challenging litigators to adapt to the evolving requirements. Let’s take a look at five recent cases to see how courts are putting these requirements into practice—insights that will prove particularly valuable for litigators planning their expert strategy.
December 18, 2024 — Report WIT Hatch-Waxman Report: Judge Michael Shipp Our latest Hatch-Waxman report provides a comprehensive analysis of Judge Michael Shipp's activity at the United States District Court for the District of New Jersey since his appointment in July 2012. Learn more about our findings.
October 23, 2024 — Blog Life Sciences Roundup: Top Insights from Q2 – Q3 Life sciences companies face mounting litigation over patents, products, and pricing practices. Successfully navigating these matters requires expertise from qualified experts and an expert agency focused on arising litigation trends. Check out our insights.
June 18, 2024 — Report A National Study of Community Attitudes Toward Pharmaceutical Companies WIT commissioned the DOAR Research Center to conduct a national study of community attitudes toward pharmaceutical companies and several issues suspected of creating bias. Learn more about their findings.
June 12, 2024 — Report WIT Hatch-Waxman Report: Senior Judge Richard Andrews Our latest Hatch-Waxman report provides a comprehensive analysis of Senior Judge Richard Andrews' activity at the United States District Court for the District of Delaware since his appointment in November 2011. Learn more about our findings.
October 2, 2023 — Blog Expert Perspective: What is Driving Growth and Litigation in the Biotechnology Space? The biotechnology market is headed towards transformational growth as the landscape shifts, resulting from impending patent cliffs, increased M&A activity, and ongoing innovation. WIT biotech expert Peter Lankau provides insights on what's to come in the industry for the remainder of this year and beyond.
July 26, 2023 — Blog Big Pharma’s Balancing Act: Navigating Patent Thickets in the Age of Biosimilars Biosimilar patent cases are complex legal battles that require the support of various experts to bolster the nuanced arguments presented by pharmaceutical companies.
May 17, 2023 — Blog Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more.
April 4, 2023 — Press Release WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets.
February 22, 2023 — Blog Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP.
July 14, 2021 — Blog FDA Approvals, Controversial Therapeutics, and the Experts Needed for Litigation Therapeutics are some of the most complicated, most regulated, and most litigated products existing in the market today. Any inconsistencies to the qualification and validation protocols of the product can cause undue harm, lasting damage, and unlimited claims of liability.
